Member Info for hunkymonkey

Oh and riddler, please stop with the childish name calling, if you have anything constructive to add, please do so, if you disagree - please do so and back it up with rns and facts.

Nice find on gsk incidentally

Why would I, good question
2019 revs $6.8mln - net loss $1mln
2018 rev $6mln - net loss $900k
2017 rev $5.4mln - net loss $900k

2020 revs $5mln.

Well, firstly I argue that how much have the figures improved given the tech? 2019 brought a single contact of £1.1 mln, which throughout the years of accounts is an anomaly (I also have opinions on this but are speculation). that's disregarding 2020 figures because as you say, a ****e year to be expected

So what is the net loss going to be? I really want to see the eoy accounts for cash position. Simple as that. Loans from the BoD are due to be paid or diluted September this year, I want to see how much of the loan facility is actually being used, as for a company who hasn't produced a net profit, won't be helped by interest charges of credit

I genuinely believe that we should be doing revenues of double what we are, it's not new tech anymore - lokies has been out for two years. Failure to establish decent contracts in that time means competitors catch up or get a foot hold before us. I'm so frustrated with the distribution of really good tech ultimately and I believe that they have had time to deliver.

Good post, I agree and hope you're right. All on the eoy accounts for me now

Please do, you'll see what I saw. I like to look at everything, get back with what you think. I've also read further. So your opinion would be appreciated, and I'll get back with my updated opinion

Look when corporation tax is due 5 months after eoy, look at when traditionally raises have been? That's where I got that info from

Look at the Earnings Before Interest, Taxes, Depreciation, and Amortization, compared to net profit.

That stemmed from reading into the corporation tax in israel, they calculate tax based on revenue, not profits. Google it read into it.

I've been saying for ages that with the tech- I feel that they should have been doing better (which I stand by). This deal though might just be it. I still want to see the accounts, but this could just be the deal, I/we have been waiting for

Fair play, great find, looks like a very good prospect

Should be really interesting, we will know where we stand for the year imminently

Got a link to the new gsk link? Would like to read the original verified source. On twitter it's just a screen shot with no link

Big growth sector indeed.

How much was the market worth for 2015-2019?

https://www.biopharminternational.com/view/accelerating-technology-adoption-to-track-the-cold-chain

Interesting to note the company "csafe" they make reference to $65mln revs founded 2013

https://www.zoominfo.com/c/csafe-global-company/348594960

I thought they were okay for cash, but certainly the above makes me think, things could be tighter. I find it useful to attach figures from rns'd, rather than simply accepting people saying the positives about cash.

In addition to the above, it's also noteworthy that corporation tax is due on 30/05/21 approximately $1mln and the BoD loans from 25/03/20 are due to be paid or diluted at the latest 30/09/21.

Rather than getting into the remit which this BB can be good at of, placing, no placing, you're a deramper etc.

I'll share some figures

$158k cash on 2/3/2020 rns
$204k in BoD loans (inc 39k pymt to BoD) 25/03/20 rns
$230k in government loan 10/12/20 rns
$175k in grants on 10/12/20 rns

$729k in cash and cash equivalent all rns'd

They have clear had revenues also

The unaudited accounts on 20/08/20 - rns

This showed an unaudited loss of $716k

The net loss for last year was approx $1mln, I hypothesised that with the expected reduced revenues, for last year the loss would be approx $1.5mln

But they have also received revenues this year

The only thing I haven't mentioned is the credit facility of $1.1mln, but this is to be utilised more for contract wins and avoided raising to fulfill orders, it was not really designed for cash flow

I've thought this through, a possible scenario maybe... Perhaps an existing client has just started transporting covid related items, therefore not new business and therefore not rns worthy? I can't imagine that given the mcap, pretty much any half decent new contract will warrant an rns. No idea, but trying to apply logic

Just to do with work draft, really good operation in delivering. I don't know any 70+ who haven't had it now, 60+ surely to be the next to roll out. Although, I know a football coach (31 yr old), with a young daughter and a child on the way, who recently passed, you just don't know how it's going to affect you. Kind of makes all those silly twitter spats seem insignificant

I've now had the covid vaccine today. Fair play too the UK, what an efficient slick operation we are running. Credit where credit is due

At least you aren't duplicitous

The money definitely not happy with the BoD